Test your knowledge about decision making in the CLL frontline setting

Which of the following Bruton’s tyrosine kinase (BTK) inhibitors have demonstrated the lowest rates of hypertension across key clinical trials in patients with CLL?
Ibrutinib
Acalabrutinib
Zanubrutinib
When compared with ibrutinib, acalabrutinib demonstrated which of the following: Improved progression-free survival (PFS)
Lower incidence of headaches
Decreased incidence of atrial fibrillation and hypertension
Once daily dosing
Del(17p) is associated with favorable outcomes and less aggressive disease in patients with CLL.
True
False
When compared with ibrutinib, zanubrutinib demonstrates which of the following in patients with CLL?
Improved PFS rates
Increased rates of COVID-19 infections
Decreased incidence of atrial fibrillation
All of the above
{"name":"Test your knowledge about decision making in the CLL frontline setting", "url":"https://www.poll-maker.com/QJOTJV0CU","txt":"Which of the following Bruton’s tyrosine kinase (BTK) inhibitors have demonstrated the lowest rates of hypertension across key clinical trials in patients with CLL?, When compared with ibrutinib, acalabrutinib demonstrated which of the following: Improved progression-free survival (PFS), Del(17p) is associated with favorable outcomes and less aggressive disease in patients with CLL.","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}